# Mechanisms of Refractory Hypertension (Reserpine)

> **NCT03223272** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 7 (actual)

## Conditions studied

- Refractory Hypertension

## Interventions

- **DRUG:** Reserpine

## Key facts

- **NCT ID:** NCT03223272
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-23
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-01-31
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03223272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03223272, "Mechanisms of Refractory Hypertension (Reserpine)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03223272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*